Skip to content

Ironwood Pharmaceuticals

US · IRWD #3609 by market cap
4.70 -0.01 -0.21%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

Recent news

  • More Money In The Bank For Ironwood Pharmaceuticals Insiders Who Divested US$1.3m
    Simply Wall St · 2026/11/9
  • Ironwood Pharmaceuticals Raises 2026 View To Rev $485M-$510M IRWD
    Dow Jones · 2026/11/5
  • Company notice
    Ironwood Pharmaceuticals | 10-Q: Quarterly report
    SEC · 2026/11/6
  • Company notice
    Ironwood Pharmaceuticals | SCHEDULE 13G: Others
    SEC · 2026/11/10
  • Company notice
    Ironwood Pharmaceuticals | 8-K: Current report
    SEC · 2026/11/5
  • Rating change
    Wells Fargo Maintains Ironwood Pharmaceuticals(IRWD.US) With Hold Rating, Maintains Target Price $5
    Market Newswire · 2026/5/6
  • Craig-Hallum Maintains Ironwood Pharmaceuticals(IRWD.US) With Buy Rating, Announces Target Price $6
    Market Newswire · 2026/11/6
  • Rating change
    Citizens JMP Maintains Ironwood Pharmaceuticals(IRWD.US) With Buy Rating, Raises Target Price to $10
    Market Newswire · 2026/2/26
  • Rating change
    Ironwood Pharmaceuticals Raised to Market Outperform From Market Perform by Citizens
    Dow Jones · 2026/1/5
  • Rating change
    Craig-Hallum Maintains Ironwood Pharmaceuticals(IRWD.US) With Buy Rating
    Market Newswire · 2026/7/16
  • Rating change
    Citizens JMP Upgrades Ironwood Pharmaceuticals(IRWD.US) to Buy Rating, Announces Target Price $8
    Market Newswire · 2026/1/5
  • Rating change
    Ironwood Pharmaceuticals Analyst Ratings
    Benzinga · 2026/1/5
  • Rating change
    Wells Fargo Maintains Ironwood Pharmaceuticals(IRWD.US) With Hold Rating, Raises Target Price to $5
    Market Newswire · 2026/1/5
  • Rating change
    Analysts' Top Healthcare Picks: Ironwood Pharma (IRWD), Sionna Therapeutics, Inc. (SION)
    TipRanks · 2026/5/14
  • Rating change
    Analysts Conflicted on These Healthcare Names: Terns Pharmaceuticals (TERN) and Ironwood Pharma (IRWD)
    TipRanks · 2025/11/26
  • Company notice
    Ironwood Pharmaceuticals | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
    SEC · 2026/11/6
  • Rating change
    Craig-Hallum Upgrades Ironwood Pharmaceuticals(IRWD.US) to Buy Rating, Raises Target Price to $5.7
    Market Newswire · 2026/1/5
  • Ironwood Pharmaceuticals Q3 Adj. EPS $0.36 Beats $0.32 Estimate, Sales $133.040M Beat $121.567M Estimate
    Benzinga · 2026/11/5
  • Company notice
    Ironwood Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
    SEC · 2026/11/14
  • Ironwood Pharmaceuticals Appoints Tammi Gaskins CEO, Effective Jan. 1, 2027
    Benzinga · 2026/10/16
  • Company notice
    Ironwood Pharmaceuticals | SCHEDULE 13G/A: Others
    SEC · 2026/8/14
  • Ironwood Pharmaceuticals' Earnings Call Highlights LINZESS Surge
    TipRanks · 2026/8/7
  • Ironwood Pharmaceuticals Q2 Adj. EPS $0.31 Misses $0.36 Estimate, Sales $113.041M Miss $114.844M Estimate
    Benzinga · 2026/8/6
  • Ironwood Pharmaceuticals Reports Mixed Q2 Results; Raises FY26 Outlook
    Seeking Alpha · 2026/8/6
  • Company notice
    Ironwood Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
    SEC · 2026/9/24

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 20:01:04 · For reference only, not investment advice and not tailored to your situation.

Ironwood Pharmaceuticals discussion 0 comments

Add a comment